Transformative period with good progress across the business

LONDON, 31 July 2017:

Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience”, “Arix” or the “Company”), a global life sciences company supporting medical innovation, today announces its financial results for the six-month period ended 30 June 2017.


  • Successful IPO on the Main Market of the London Stock Exchange in February 2017, raising £112 million of new proceeds to use in sourcing, financing and developing young businesses to address important areas of unmet medical need.
  • Acquired direct interests in 5 new Arix Group Businesses, bringing the total portfolio to 10 Group Businesses
    • Led a $65 million Series B investment round for Iterum, developing differentiated anti-infectives with its lead candidate entering Phase III trials; Arix has a seat on the Board
    • Co-led a $45 million Series B investment round for Harpoon Therapeutics, developing a novel immuno-oncology antibody platform; Arix has a seat on the Board
    • Led a $45 million Series B investment round for LogicBio, focused on breakthrough, disease-modifying gene therapies for orphan paediatric diseases; Arix has a seat on the Board
    • Participated in a $20 million Series A investment round for Mitoconix Bio, developing novel treatments to improve mitochondrial function for neurodegenerative disorders including Huntington’s, Parkinson’s and Alzheimer’s; Arix has a Board Observer role
    • After the period end, co-led a $29 million Series A financing for PreciThera, developing novel biological therapeutics for orphan bone diseases; Arix has a seat on the Board
    • Encouraging progress in the development of existing Arix Group Businesses
      • Verona Pharma plc successfully listed on NASDAQ, raising c. $80 million
      • Autolus, the T cell immunotherapy company focused on the treatment of cancer, is set to commence three clinical trials in multiple myeloma, non-Hodgkin’s lymphoma and T cell lymphoma
      • Artios formed a Scientific Advisory Board comprising several leading experts in the field of DNA damage response, DNA genetics and drug discovery
      • Depixus awarded the Concours Mondial d’Innovation in France, in recognition of its leadership in scientific innovation
  • Good progress in our strategic partnerships with Takeda and UCB Pharma, with a focus on developing new business opportunities in our areas of common therapeutic interest, and supported by the secondment to Arix of a senior UCB executive during the period
  • Advanced the Company’s partnership with the Max Planck Lead Discovery Center in Germany with experimental work underway around a promising new target in metabolic disease in collaboration with the University of Leeds
  • Continued to build our close strategic partnership with BioMotiv in the US offering privileged access to a broad portfolio of promising academic programs and subsequent business building opportunities
  • Strong and sustained pipeline of high quality opportunities: Arix accessed and reviewed over 700 potential opportunities over the past year
  • Period-end cash balance of £108 million
  • Capital Markets Day planned for 18 September in London at which a number of our Group Businesses will present their businesses

Dr Joe Anderson, Chief Executive Officer of Arix Bioscience, commented: “I am pleased to report good progress on our goal of building interests in highly innovative young life sciences companies, adding five high quality Group Businesses to our portfolio since IPO.

“Looking ahead, we continue to see a rich pipeline of potential new opportunities to further build our portfolio, and will continue to actively support the development our 10 current Group Businesses. We look forward to our inaugural Capital Markets Day in London on 18 September 2017, at which the CEOs of a number of our Group Businesses will present on their progress.

“Led by our experienced team, Arix Bioscience is progressing its goals of advancing innovation in medicine for the benefit of patients and offering access to a high potential portfolio of young life science companies, for public shareholders.”